AR073073A1 - Compuestos de pirrolo [ 2,3-d] pirimidina. - Google Patents

Compuestos de pirrolo [ 2,3-d] pirimidina.

Info

Publication number
AR073073A1
AR073073A1 ARP090103164A ARP090103164A AR073073A1 AR 073073 A1 AR073073 A1 AR 073073A1 AR P090103164 A ARP090103164 A AR P090103164A AR P090103164 A ARP090103164 A AR P090103164A AR 073073 A1 AR073073 A1 AR 073073A1
Authority
AR
Argentina
Prior art keywords
compounds
methyl
pirrolo
pyrimidine
salt
Prior art date
Application number
ARP090103164A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41259411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR073073A1 publication Critical patent/AR073073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Su uso como inhibidores de Janus quinasa (JAK), composiciones farmacéuticas que contienen estos compuestos y métodos para la preparacion de estos compuestos. Reivindicacion 1: Un compuesto de formula 1 o una sal farmacéuticamente aceptable del mismo en la que R1 es -alquilo C1-4, sustituido opcionalmente con hidroxido. Reivindicacion 18: La forma A cristalina de la sal de N-metil-1-{trans-4-[metil(7H- pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida de ácido maleico segun la reivindicacion 15, que comprende un diagrama de difraccion de rayos X en polvo que tiene un pico característico expresado en grados 2-theta a aproximadamente 6,178, 8,519, 12,601, 13,819, 15,478, 15,719, 16,32, 17,997, 18,539, 20,298, 20,659, 21,583, 22,642, 23,08, 24,86, 25,602, 26,582, 27,02, 27,721, 28,161, 28,38.
ARP090103164A 2008-08-20 2009-08-18 Compuestos de pirrolo [ 2,3-d] pirimidina. AR073073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9037108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
AR073073A1 true AR073073A1 (es) 2010-10-13

Family

ID=41259411

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103164A AR073073A1 (es) 2008-08-20 2009-08-18 Compuestos de pirrolo [ 2,3-d] pirimidina.
ARP160103034A AR106252A2 (es) 2008-08-20 2016-10-04 Compuestos de pirrolo[2,3-d]pirimidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160103034A AR106252A2 (es) 2008-08-20 2016-10-04 Compuestos de pirrolo[2,3-d]pirimidina

Country Status (27)

Country Link
US (4) US8133899B2 (es)
EP (1) EP2384326B1 (es)
JP (1) JP4884570B2 (es)
KR (1) KR101335843B1 (es)
CN (1) CN102131812B (es)
AR (2) AR073073A1 (es)
AU (1) AU2009283844B2 (es)
BR (1) BRPI0917459B1 (es)
CA (1) CA2733359C (es)
CL (1) CL2011000353A1 (es)
CO (1) CO6331437A2 (es)
DK (1) DK2384326T3 (es)
EC (1) ECSP11010904A (es)
ES (1) ES2467109T3 (es)
HK (1) HK1160116A1 (es)
HR (1) HRP20140395T1 (es)
ME (1) ME01269B (es)
MX (1) MX2011001904A (es)
NZ (1) NZ605292A (es)
PL (1) PL2384326T3 (es)
PT (1) PT2384326E (es)
RS (1) RS53382B (es)
RU (1) RU2493157C2 (es)
SI (1) SI2384326T1 (es)
UY (1) UY32059A (es)
WO (1) WO2010020905A1 (es)
ZA (1) ZA201101701B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030235T2 (en) 2005-12-13 2017-04-28 Incyte Holdings Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
EA020494B1 (ru) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
KR20120083452A (ko) * 2009-10-15 2012-07-25 화이자 인코포레이티드 피롤로［2,3-ｄ］피리미딘 화합물
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
ES2461967T3 (es) * 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
MX2012009798A (es) * 2010-02-24 2012-09-12 Pfizer Composiciones veterinarias.
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
JP6129155B2 (ja) * 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR102127939B1 (ko) * 2012-07-17 2020-06-29 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴
RS58242B1 (sr) * 2012-07-20 2019-03-29 Zoetis Services Llc Režim doziranja za inhibitore janus kinaze (jak)
KR20220162825A (ko) 2012-11-15 2022-12-08 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
ME02904B (me) * 2013-02-22 2018-04-20 Pfizer DERIVATI PIROLO[2,3 -d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK)
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
UA118149C2 (uk) * 2015-01-20 2018-11-26 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор jak
PL3290418T3 (pl) 2015-04-29 2019-11-29 Wuxi Fortune Pharmaceutical Co Ltd Inhibitory kinaz janusowych (jak)
US10174056B2 (en) 2015-05-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EP3411355B1 (en) * 2016-02-05 2020-10-28 Siegfried AG Process for the preparation of trans-4-amino-1-cyclohexanecarboxylic acid
NZ744341A (en) * 2016-02-16 2019-06-28 Zoetis Services Llc Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds
CN107365312B (zh) * 2016-05-13 2021-10-01 瑞博(杭州)医药科技有限公司 一种制备Oclacitinib的新方法
WO2018108969A1 (en) 2016-12-14 2018-06-21 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
CN110662747A (zh) 2017-05-23 2020-01-07 施万生物制药研发Ip有限责任公司 Janus激酶抑制剂的葡糖苷酸前药
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
TWI797242B (zh) 2018-01-30 2023-04-01 美商英塞特公司 製備ｊａｋ抑制劑之方法及中間物
EP3765069A1 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Peptide vaccines against interleukin-31
CN112020511A (zh) 2018-03-16 2020-12-01 硕腾服务有限责任公司 用于兽医用途的白介素-31单克隆抗体
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020096948A1 (en) * 2018-11-05 2020-05-14 Avista Pharma Solutions, Inc. Chemical compounds
NL2022471B1 (en) * 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
AU2019426113B2 (en) * 2019-01-30 2022-06-16 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4077380A1 (en) 2019-12-20 2022-10-26 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112279854B (zh) * 2020-08-25 2022-04-05 常州齐晖药业有限公司 一种7H-吡咯并[2,3-d]嘧啶化合物的制备方法
JP2023545182A (ja) 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体
CA3201608A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
WO2022178201A1 (en) 2021-02-22 2022-08-25 Zoetis Services Llc Horse il-31 induced pruritus model
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis
WO2023111128A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023118555A1 (en) 2021-12-24 2023-06-29 Intervet International B.V. Use of aminopyrazole compounds
CN114605420A (zh) * 2022-04-25 2022-06-10 江苏慧聚药业股份有限公司 一条马来酸奥拉替尼的合成方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives
US3670079A (en) * 1970-10-06 1972-06-13 Merck & Co Inc Anabolic agents
US4997936A (en) * 1977-10-19 1991-03-05 Merck & Co., Inc. 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4456464A (en) * 1982-05-19 1984-06-26 Zoecon Corporation Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control
US4526608A (en) * 1982-07-14 1985-07-02 Zoecon Corporation Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use
US4590282A (en) * 1984-09-24 1986-05-20 Sandoz Ltd. Pest control agents
US4933339A (en) * 1985-08-21 1990-06-12 Rohm And Haas Company (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity
CA1328333C (en) * 1988-03-04 1994-04-05 Quirico Branca Amino acid derivatives
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
US4879309A (en) * 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
JP2983254B2 (ja) * 1989-06-14 1999-11-29 武田薬品工業株式会社 ピロロ〔２，３―ｄ〕ピリミジン誘導体の製造法およびその中間体
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
PL324486A1 (en) 1995-07-05 1998-05-25 Du Pont Fungicidal pyrimidinones
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US5965563A (en) 1995-11-14 1999-10-12 Pharmacia & Upjohn S.P.A. Aryl and heteroaryl purine compounds
JP4275733B2 (ja) 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジンおよびその製造法
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998007726A1 (en) 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CA2272705C (en) 1996-11-27 2003-03-18 Pfizer Inc. Fused bicyclic pyrimidine derivatives
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
AU6568398A (en) * 1997-03-24 1998-10-20 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
JP2002510687A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
WO1999061428A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
WO2001023389A2 (en) * 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
JP4078074B2 (ja) * 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
KR20050086784A (ko) * 2002-11-26 2005-08-30 화이자 프로덕츠 인크. 이식 거부반응의 치료 방법
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
AU2004305317A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection
EP1715871A1 (en) * 2003-12-22 2006-11-02 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1797054A2 (en) * 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Also Published As

Publication number Publication date
KR20110043697A (ko) 2011-04-27
US8133899B2 (en) 2012-03-13
UY32059A (es) 2010-03-26
US20150148357A1 (en) 2015-05-28
PL2384326T3 (pl) 2014-09-30
AU2009283844A1 (en) 2010-02-25
ZA201101701B (en) 2012-05-30
AU2009283844B2 (en) 2013-09-05
JP2012500253A (ja) 2012-01-05
PT2384326E (pt) 2014-06-09
EP2384326B1 (en) 2014-04-23
US9161939B2 (en) 2015-10-20
ME01269B (me) 2013-06-20
DK2384326T3 (da) 2014-05-05
RS53382B (en) 2014-10-31
RU2011106331A (ru) 2012-08-27
HRP20140395T1 (hr) 2014-06-06
WO2010020905A1 (en) 2010-02-25
ES2467109T3 (es) 2014-06-11
AR106252A2 (es) 2017-12-27
KR101335843B1 (ko) 2013-12-02
JP4884570B2 (ja) 2012-02-29
BRPI0917459B1 (pt) 2017-09-12
CA2733359A1 (en) 2010-02-25
EP2384326A1 (en) 2011-11-09
ECSP11010904A (es) 2011-04-29
US8987283B2 (en) 2015-03-24
CO6331437A2 (es) 2011-10-20
CL2011000353A1 (es) 2011-05-06
SI2384326T1 (sl) 2014-06-30
NZ605292A (en) 2014-06-27
MX2011001904A (es) 2011-03-29
CN102131812B (zh) 2014-04-09
BRPI0917459A2 (pt) 2015-12-01
US20120122901A1 (en) 2012-05-17
CN102131812A (zh) 2011-07-20
US20150374701A1 (en) 2015-12-31
HK1160116A1 (en) 2012-08-10
CA2733359C (en) 2014-08-05
US9271981B2 (en) 2016-03-01
US20100075996A1 (en) 2010-03-25
RU2493157C2 (ru) 2013-09-20

Similar Documents

Publication Publication Date Title
AR073073A1 (es) Compuestos de pirrolo [ 2,3-d] pirimidina.
RS53574B1 (en) PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
SI2725028T1 (sl) Substituirane spojine pirazolo(1,5-)pirimidina kot vmesne spojine v sintezi inhibitorjev TRK kinaze
AR091138A1 (es) Proceso para la preparacion de n-[5-(3,5-difluorobencil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetrahidropiran-4-ilamino)-benzamida
MX2016006336A (es) Compuestos pirazolopirimidina.
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
CU20120059A7 (es) Compuestos de pirrolo[2,3-d]pirimidina
EA201270046A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
CL2009000576A1 (es) Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide.
AR083870A1 (es) Inhibidores de la replicacion del vih
BR112012019511A2 (pt) compostos de pirrolo [2,3-d] pirimidina como inibidores de jak.
MX2015016877A (es) Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.
AR045628A1 (es) Variedades cristalinas de bis-(acido(e)-7-{4-(4-fluorofenil)-6-isopropil-2-[¨metil(metilsulfonil)amino]pirimidin-5-il} (3r,5s)-3,5 dihidroxihept-6-enoico)
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
TW200616976A (en) Pyrimidine derivatives
MY144016A (en) Process for the production of methyl (e)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
NZ707213A (en) Compositions and methods of treating pulmonary hypertension
EA201170118A1 (ru) Циклопропильные ингибиторы полимеразы
UA99735C2 (uk) Конденсовані біциклічні піримідини
NZ629122A (en) Liver x receptor modulators

Legal Events

Date Code Title Description
FC Refusal